Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
JPEN J Parenter Enteral Nutr. 2022 Nov;46(8):1761-1768. doi: 10.1002/jpen.2415. Epub 2022 Jun 19.
The purpose of the present meta-analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample.
MEDLINE, Cochrane, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. The meta-analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random-effects models with inverse-variance weights were used.
The included 280 studies comprised 81,814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia >50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas, and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of low skeletal muscle mass was <35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% (P< 0.001).
Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is higher in palliative setting vs curative setting. The prevalence of sarcopenia is also different in different tumors.
本荟萃分析的目的是基于大样本分析不同恶性实体瘤患者在不同肿瘤学背景下分期计算机断层扫描（CT）中肌少症的流行情况。
截至 2021 年 12 月，我们在 MEDLINE、Cochrane 和 SCOPUS 文献数据库中筛选了肿瘤患者肌少症的流行情况。共有 280 项研究符合纳入标准。根据诊断研究质量评估工具检查纳入研究的方法学质量。使用 RevMan 5.4 软件进行荟萃分析。采用逆方差权重的 DerSimonian 和 Laird 随机效应模型。
纳入的 280 项研究包括 81814 名患有不同肿瘤的患者。所有纳入研究中肌少症的患病率为 35.3%。食管癌、尿路上皮癌、胆管癌、前列腺癌、肉瘤和甲状腺癌中肌少症的患病率>50%。在头颈部鳞状细胞癌、胰腺癌、肺癌、肾细胞癌和卵巢癌中，肌少症的患病率在 35%至 50%之间。在结直肠癌、胃癌、肝细胞癌和乳腺癌中，低骨骼肌量的患病率<35%。在根治性治疗中，肌少症的患病率为 39.6%，在姑息性治疗中，患病率为 49.2%（P<0.001）。
肌少症是一种常见的肿瘤学疾病，患病率为 35.3%。姑息治疗中肌少症的患病率高于根治性治疗。不同肿瘤中肌少症的患病率也不同。
